透析前甲状腺功能与终末期肾病早期透析死亡率的相关性
本研究基于美国退伍军人事务部数据库,纳入2007年10月至2011年9月期间新进入透析的慢性肾脏病(CKD)患者,分析透析前1年(「前奏期」)平均促甲状腺激素(TSH)水平与透析后第一年全因死亡率的关系。结果发现,透析前TSH>5.0 mIU/L与透析后1年死亡率升高独立相关,且TSH水平越高死亡率越高,呈剂量依赖性。
要点
- 透析前TSH>5.0 mIU/L与新进入透析患者1年全因死亡率升高相关(aHR 1.20)。
- TSH水平>5.0-10.0和>10.0 mIU/L时,死亡率风险呈递增趋势。
- 该关联在2年和5年前奏期队列中亦持续存在,尤以TSH>10.0 mIU/L者显著。
核心结论
- 在新进入终末期肾病(ESRD)的患者中,透析前TSH水平>5.0 mIU/L与透析后死亡率呈剂量依赖性正相关。
研究设计与样本
- 分别评估透析前1年、2年和5年平均TSH水平与透析后1年全因死亡率的关系,采用扩展病例混合Cox模型。
主要发现
- 在1年前奏期队列中,TSH>5.0 mIU/L(参考0.5-5.0 mIU/L)与1年全因死亡率升高相关,aHR为1.20(95%CI 1.07-1.33)。
- 在2年和5年前奏期队列中,TSH>5.0 mIU/L与死亡率的相关性分别为aHR 1.11(95%CI 1.02-1.21)和1.15(95%CI 1.07-1.24)。
- 在1年前奏期队列中,TSH水平>5.0-10.0 mIU/L和>10.0 mIU/L(参考0.5-3.0 mIU/L)的aHR分别为1.18(95%CI 1.04-1.33)和1.28(95%CI 1.03-1.59)。
- 在2年和5年队列中,TSH>10.0 mIU/L者的死亡率关联最强,尤其在调整实验室协变量后。
临床怎么用
- 对于进展至ESRD的CKD患者,透析前应关注TSH水平,TSH>5.0 mIU/L可能提示透析后早期死亡风险增加。
- 目前尚无证据支持通过甲状腺激素补充降低TSH来改善透析后生存,需进一步研究。
局限性
- 研究为观察性设计,无法确定TSH水平与死亡率之间的因果关系。
- 研究对象为美国退伍军人,结果外推至其他人群需谨慎。
- 原文未报告甲状腺激素替代治疗对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced chronic kidney disease (CKD) patients, including those receiving dialysis, have a high prevalence of thyroid dysfunction. Although hypothyroidism is associated with higher death risk in end-stage renal disease (ESRD) patients, no studies have examined whether thyroid status in the pre-ESRD period impacts mortality after dialysis initiation. METHODS: Among US veterans with CKD identified from the national Veterans Affairs database that transitioned to dialysis over the period from October 2007 to September 2011, we examined the association of pre-ESRD serum thyrotropin (TSH) levels averaged over the 1-year pre-dialysis ('prelude') period with all-cause mortality in the first year following dialysis initiation. RESULTS: Among 15 335 patients in the 1-year prelude cohort, TSH levels >5.0 mIU/L were associated with higher mortality in expanded case-mix Cox models (reference: TSH 0.5-5.0 mIU/L): adjusted hazard ratio (aHR) [95% confidence interval (CI) 1.20 (1.07-1.33). Similar findings were observed for TSH >5.0 mIU/L and mortality in the 2- and 5-year cohorts: aHRs (95% CI) 1.11 (1.02-1.21) and 1.15 (1.07-1.24), respectively. Analyses of finer gradations of TSH in the 1-year prelude cohort demonstrated that incrementally higher levels >5.0 mIU/L were associated with increasingly higher mortality in expanded case-mix models (reference: TSH 0.5-3.0 mIU/L): aHRs (95% CI) 1.18 (1.04-1.33) and 1.28 (1.03-1.59) for TSH levels >5.0-10.0 mIU/L and >10.0 mIU/L, respectively. In the 2- and 5-year cohorts, mortality associations persisted most strongly for those with TSH >10.0 mIU/L, particularly after laboratory covariate adjustment. CONCLUSIONS: Among new ESRD patients, there is a dose-dependent relationship between higher pre-ESRD TSH levels >5.0 mIU/L and post-ESRD mortality. Further studies are needed to determine the impact of TSH reduction with thyroid hormone supplementation in this population.
引用
- You AS, Sim JJ, Kovesdy CP, et al. Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Nephrol Dial Transplant. 2019. PMID: 30299498. doi:10.1093/ndt/gfy289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。